Heron Therapeutics, Inc. (0J4V.L)
USD 1.62
(0.31%)
USD 1.62
(0.31%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 222.5 Million USD | -11.33% |
| 2022 | 250.95 Million USD | -17.91% |
| 2021 | 305.7 Million USD | -13.53% |
| 2020 | 353.55 Million USD | -31.05% |
| 2019 | 512.78 Million USD | 10.95% |
| 2018 | 462.17 Million USD | 97.25% |
| 2017 | 234.3 Million USD | 247.21% |
| 2016 | 67.48 Million USD | -51.05% |
| 2015 | 137.84 Million USD | 79.76% |
| 2014 | 76.68 Million USD | 0.98% |
| 2013 | 75.93 Million USD | 35.67% |
| 2012 | 55.97 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 217.88 Million USD | -2.08% |
| 2024 Q2 | 218.13 Million USD | 0.11% |
| 2023 Q2 | 201.22 Million USD | -8.9% |
| 2023 Q1 | 220.87 Million USD | -11.98% |
| 2023 Q3 | 229.19 Million USD | 13.9% |
| 2023 Q4 | 222.5 Million USD | -2.92% |
| 2023 FY | 222.5 Million USD | -11.33% |
| 2022 Q2 | 243.96 Million USD | -10.87% |
| 2022 Q1 | 273.72 Million USD | -10.46% |
| 2022 FY | 250.95 Million USD | -17.91% |
| 2022 Q4 | 250.95 Million USD | -7.72% |
| 2022 Q3 | 271.95 Million USD | 11.47% |
| 2021 Q4 | 305.7 Million USD | -13.25% |
| 2021 Q3 | 352.38 Million USD | -12.83% |
| 2021 FY | 305.7 Million USD | -13.53% |
| 2021 Q1 | 310.93 Million USD | -12.06% |
| 2021 Q2 | 404.25 Million USD | 30.01% |
| 2020 Q1 | 478.94 Million USD | -6.6% |
| 2020 FY | 353.55 Million USD | -31.05% |
| 2020 Q2 | 432.72 Million USD | -9.65% |
| 2020 Q3 | 390.02 Million USD | -9.87% |
| 2020 Q4 | 353.55 Million USD | -9.35% |
| 2019 Q4 | 512.78 Million USD | 30.49% |
| 2019 Q3 | 392.96 Million USD | -4.54% |
| 2019 Q2 | 411.66 Million USD | -5.54% |
| 2019 Q1 | 435.79 Million USD | -5.71% |
| 2019 FY | 512.78 Million USD | 10.95% |
| 2018 FY | 462.17 Million USD | 97.25% |
| 2018 Q4 | 462.17 Million USD | -1.85% |
| 2018 Q3 | 470.89 Million USD | -7.77% |
| 2018 Q2 | 510.55 Million USD | 178.41% |
| 2018 Q1 | 183.38 Million USD | -21.73% |
| 2017 Q3 | 118.19 Million USD | -16.98% |
| 2017 FY | 234.3 Million USD | 247.21% |
| 2017 Q2 | 142.37 Million USD | -24.89% |
| 2017 Q1 | 189.55 Million USD | 180.9% |
| 2017 Q4 | 234.3 Million USD | 98.24% |
| 2016 Q3 | 98.8 Million USD | 15.25% |
| 2016 Q2 | 85.73 Million USD | -23.35% |
| 2016 Q4 | 67.48 Million USD | -31.7% |
| 2016 FY | 67.48 Million USD | -51.05% |
| 2016 Q1 | 111.84 Million USD | -18.86% |
| 2015 FY | 137.84 Million USD | 79.76% |
| 2015 Q1 | 59.62 Million USD | -22.24% |
| 2015 Q4 | 137.84 Million USD | -12.84% |
| 2015 Q3 | 158.15 Million USD | -10.37% |
| 2015 Q2 | 176.45 Million USD | 195.93% |
| 2014 FY | 76.68 Million USD | 0.98% |
| 2014 Q2 | 108.63 Million USD | 73.01% |
| 2014 Q3 | 92.28 Million USD | -15.06% |
| 2014 Q4 | 76.68 Million USD | -16.9% |
| 2014 Q1 | 62.79 Million USD | -17.31% |
| 2013 Q3 | 26.37 Million USD | -30.77% |
| 2013 Q2 | 38.09 Million USD | -22.23% |
| 2013 Q4 | 75.93 Million USD | 187.97% |
| 2013 Q1 | 48.97 Million USD | -12.49% |
| 2013 FY | 75.93 Million USD | 35.67% |
| 2012 Q4 | 55.97 Million USD | 0.0% |
| 2012 FY | 55.97 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 55.423% |
| Dynavax Technologies Corporation | 997.09 Million USD | 77.685% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 84.208% |
| Perrigo Company plc | 10.8 Billion USD | 97.941% |
| Illumina, Inc. | 10.11 Billion USD | 97.799% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.775% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 71.486% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.725% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.166% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.327% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -238.721% |
| Waters Corporation | 4.62 Billion USD | 95.191% |
| Biogen Inc. | 26.84 Billion USD | 99.171% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -34.591% |
| Evolus, Inc. | 188.99 Million USD | -17.729% |
| Adicet Bio, Inc. | 207.29 Million USD | -7.338% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -76.811% |
| bluebird bio, Inc. | 619.16 Million USD | 64.063% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -8.12% |
| FibroGen, Inc. | 423.52 Million USD | 47.464% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 97.933% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -687.008% |
| Homology Medicines, Inc. | 47.05 Million USD | -372.844% |
| Geron Corporation | 394.07 Million USD | 43.537% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.19% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 71.396% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 81.438% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 39.617% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 82.897% |
| Zoetis Inc. | 14.28 Billion USD | 98.442% |
| Abeona Therapeutics Inc. | 64 Million USD | -247.655% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 93.369% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.748% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.021% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -297.694% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 92.559% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -34.441% |
| Verastem, Inc. | 149.71 Million USD | -48.617% |
| Nektar Therapeutics | 398.03 Million USD | 44.099% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 62.174% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -12.715% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 93.184% |
| OPKO Health, Inc. | 2.01 Billion USD | 88.939% |
| Exelixis, Inc. | 2.94 Billion USD | 92.438% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 93.157% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 64.2% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -44.123% |
| uniQure N.V. | 831.68 Million USD | 73.246% |
| Imunon, Inc. | 21.91 Million USD | -915.172% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 78.794% |
| Insmed Incorporated | 1.32 Billion USD | 83.268% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 87.163% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 76.256% |
| TG Therapeutics, Inc. | 329.58 Million USD | 32.489% |
| Incyte Corporation | 6.78 Billion USD | 96.719% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 87.874% |